Eisai Company, Limited

Eisai Inc.

Masaki Goto

Kenichi Chiba

Hiroshi Shirota

Hideki Sakurai

Yoshikazu Kuboi

Yoshihito Eguchi

Isao Yamatsu

Toshihiko Kaneko

Jean-Christophe P Harmange

Takeshi Suzuki

Shigeru Souda

Yoshimasa Machida

Mark Spyvee

Shigeki Hibi

Seiichiro Nomoto

Katsuya Tagami

Yasushi Okamoto

Kenzo Muramoto

Makoto Okita

Kouichi Katayama

Satoshi Yamamoto

Naoki Yoneda

Tomohiro Matsushima

Makoto Kotake

Yoshiyuki Kawakami

Hong Du

Ryoichi Hashida

Hideki Ono

Isao Tanaka

Fabian Gusovsky

Masayuki Tanaka

Yoshiharu Mizui

Hideto Ohhara

Masanori Fujita

John (Yuan) Wang

Akifumi Kimura

Takatoshi Kawai

Yong-Chun Shen

Megumi Kawada

Roch Boivin

Yimin Jiang

Xiang-Yi Li

Jesse Chow

Charles-André Lemelin

Hiroshi Obaishi

Ken-ichi Chiba

Ray Wood

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

The present invention provides compounds having formula (I): 

The present invention provides a compound which has cytokine production inhibitory activity and is useful for the treatment of diseases which is associated with cytokine. The compound is represented by the following general formula (I) [wherein A represents a cyclic group which may be substituted; the partial structure -DE- represents a group represented by &#x2014;CHCH&#x2014; or &#x2014;CH&#x2550;CH&#x2014;; W represents a group represented by &#x2014;CH&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;CH&#x2550;; the partial structure &#x3e;XY&#x2014; represents a group represented by &#x3e;CH&#x2014;(CH)&#x2014;, &#x3e;C&#x2550;CH&#x2014;, &#x3e;CH&#x2014;CH&#x2014;CH(OH)&#x2014;, &#x3e;CH&#x2014;CH&#x2014;C(&#x2550;O)&#x2014;, &#x3e;CH&#x2014;O&#x2014; or &#x3e;CH&#x2014;O&#x2014;CO&#x2014;, provided that when W is &#x2014;CH&#x2550;, then XY&#x2014; represents C&#x2014;(CH)&#x2014;; Z represents a divalent aliphatic hydrocarbon group; Rand R, which may be the same or different, each represents a hydrogen atom, or a hydroxyl, alkoxy or alkoxyalkoxy group; m is an integer of 0 or 1].

Cyclooctanone derivatives and cyclodecanone derivative, and use thereof

Naphthalene derivatives of the formula: ##STR1## wherein R.sup.1, represents a hydrogen atom, a lower alkyl group or an acyl group; R.sup.2 independently represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogen atom, a cycloalkyl group, a cycloalkylalkyl group, a hydroxyl group, an aryl group which may be substituted, an arylalkyl group whose aryl group may be substituted, a heteroaryl group, or a heteroaryllakyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, an aryl group which may have a substituent, an arylalkyl group whose aryl group may be substituted, an arylalkenyl group whose aryl group may be substituted, a cycloalkyl group, an alkoxyalkyl group, a heteroaryl group, a heteroarylalkyl group, a carboxyl group, a carboxyalkyl group, an aminoalkyl group, or a cyano group; R.sup.6 is C.sub.1-6 alkyl; and m is 0 or an integer of from 1 to 2 useful in treating autoimmune diseases are disclosed.

Naphthalene derivative

A naphthalene derivative having the formula is new and useful for medicine. ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an acyl group;

A naphthalene derivative having the formula is new and useful for medicine. ##STR1## [wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an acyl group;

Growing community of inventors

Tsuchiura, Japan

Masaki Goto